You are here

Our science / Clinical Trials / Find a Trial / NCT00228397

Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

Back to Search Print Save as PDF Bookmark Trial

NCT00228397

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Relapsing-Remitting Multiple Sclerosis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with relapsing-remitting MS or secondary progressive MS with relapses.

- Successful completion of study 3066A2-205-WW with no major protocol violations.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnancy or lactation.

- Clinically important abnormalities on the physical examination, vital signs, or
electrocardiogram (ECG) performed at the last visit of study 3066A2-205-WW (day 252).

- Any adverse events or findings observed in study 3066A2-205-WW that in the opinion of
the investigators would preclude the subject's entry into the extension study.

Please refer to section 16.2 'Discontinuation and Withdrawal of Subjects' regarding
withdrawal of patients who have any clinical abnormalities in hematology or laboratory test
results obtained at the last visit of the double-blind active phase of study 3066A2-205-WW.

NCT00228397
Pfizer
Completed
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Multiple Myeloma
Phase I study of Relapsed / Refractory Multiple Myeloma
NCT03269136
All Genders
18+
Years
Multiple Sites
Focal Segmental Glomerulosclerosis (FSGS)
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
NCT03448692
All Genders
18+
Years
Multiple Sites
Neoplasms, Thrombocytopenia, Multiple Myeloma, Malignant Lymphoma
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00037791
All Genders
18+
Years
Multiple Sites
Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease
NCT00134173
All Genders
18+
Years
Multiple Sites
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis.
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Treatment
Multiple Sclerosis, Relapsing-Remitting
Drug: CCI-779
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
221
November 2005
November 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with relapsing-remitting MS or secondary progressive MS with relapses.
  • Successful completion of study 3066A2-205-WW with no major protocol violations.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Clinically important abnormalities on the physical examination, vital signs, or electrocardiogram (ECG) performed at the last visit of study 3066A2-205-WW (day 252).
  • Any adverse events or findings observed in study 3066A2-205-WW that in the opinion of the investigators would preclude the subject's entry into the extension study.

Please refer to section 16.2 'Discontinuation and Withdrawal of Subjects' regarding withdrawal of patients who have any clinical abnormalities in hematology or laboratory test results obtained at the last visit of the double-blind active phase of study 3066A2-205-WW.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00228397
3066A2-210
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
February 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now